HC006
Phase 1Small molecule
HC006 is one of 69 small molecule programs targeting Advanced Solid Tumors. It is currently in Phase 1.
2
Indications
3
Total Trials
3
Active Trials
68
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
311 competitors in Advanced Solid Tumors
#DrugCompanyPhaseTrials
1Abraxane
Bristol-Myers SquibbPhase 2
Yervoy
Bristol-Myers SquibbPhase 2
Cytoxan
BBaxter Healthcare Corporation
Phase 2
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 2
Ibrance
PfizerPhase 2
Alimta
SShawn Eagle
Phase 2
Myrbetriq
AstellasPhase 2
Xeloda
EEngelhard Arzneimittel GmbH & Co.KG
Phase 2
Faslodex
FFresenius Kabi USA, LLC
Phase 2
Rapamune
PPrism Pharmaceuticals
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Advanced Solid Tumors2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for HC006. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- HHC Biopharma Inc.